Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function

Journal of Clinical Pharmacology

Volumn 43, Issue 12, 2003, Pages 1361-1369

  Liang, Earvin ^a   Wong, Nancy ^a   Allen, Irma ^a   Kao, Richard ^b   Marino, Mark ^b   DiLea, Clifford ^b,c  

^a EISAI RESEARCH INSTITUTE   (United States)

^b EISAI INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

E5564; Lipopolysaccharide; Pharmacokinetics; Sepsis syndrome

Indexed keywords

ANTIINFLAMMATORY AGENT; E 5564; LIPOPOLYSACCHARIDE ANTAGONIST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INFUSION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER DISEASE; LIVER FUNCTION; MALE; MASS SPECTROMETRY; SIDE EFFECT;

ADULT; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIPID A; LIPOPOLYSACCHARIDES; LIVER CIRRHOSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TISSUE DISTRIBUTION;

EID: 0242721762     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258653     Document Type: Article

References (37)

1. Parker MM, Parrillo JE: Septic shock: hemodynamics and pathogenesis. JAMA 1983;250:3324-3327.
2. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients. Aro J Med 1980;68:344-355.
3. Deitch EA: Infection in the compromised host. Surg Clin North Am 1988;68:181-197.
4. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 1991;99:169-175.
5. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF: Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991;5:2652-2660.
6. Smith CR, Straube RC, Ziegler EJ: HA-1A: a human monoclonal antibody for the treatment of gram-negative sepsis. Infect Dis Clin North Am 1992;6:253-266.
7. Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Ann Rev Biochem 1977;46:723-763.
8. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266:1097-1102.
9. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-1843.
10. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-327.
11. Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994;22:1720-1728.
12. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-918.
13. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658.
14. von der Möhlen MA, Kimmings AN, Wedel NI, Mevissen ML, Jansen J, Friedmann N, et al: Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 1995;172:144-151.
15. Revhaug A, Michie HR, Manson JM, Watters JM, Dinarello CA, Wolff SM, et al: Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 1988;123:162-170.
16. Astiz ME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, et al: Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med 1995;23:9-17.
17. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl Med 1988;318:1481-1486.
18. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al: A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995;154:5492-5499.
19. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HS, Stiles DM, Pribble J, et al: Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol 1995;154:1499-1507.
20. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-5045.
21. Christ WJ, Asano O, Robidoux AL, Perez M, Wang Y, Dubuc GR, et al: E5531, a pure endotoxin antagonist of high potency. Science 1995;268:80-83.
22. Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, et al: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000;28:2713-2720.
23. Yang H, Daun JM, Rose JR, Christ WJ, Gusovsky F, Chow JC: Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531. J Endotoxin Res 2000;6:447-452.
24. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al: Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003;304:1093-1102.
25. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, et al: Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003;187:631-639.
26. Hwang TL, Lue MC, Chen LL: Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function. Hepatogastroenterology 2000;47:1347-1350.
27. Satoi S, Kamiyama Y, Kitade H, Kwon AH, Takahashi K, Wei T, et al: Nitric oxide production and hepatic dysfunction in patients with postoperative sepsis. Clin Exp Pharmacol Physiol 2000;27:197-201.
28. Hawker F: Liver dysfunction in critical illness. Anaesth Intensive Care 1991;19:165-181.
29. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R: Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;2:72-74.
30. Ellison RT III, Mason SR, Kohler PF, Curd JG, Reller LB: Meningococcemia and acquired complement deficiency: association in patients with hepatic failure. Arch Intern Med 1986;146:1539-1540.
31. Child CG III, Turcotte JG: Surgery and portal hypertension, in: Child CG III (ed.), The Liver and Portal Hypertension. Philadelphia: W. B. Saunders, 1964;50-64.
32. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br Surg 1973;60:646-649.
33. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
34. U.S. Department of Health and Human Services: Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research, 1999.
35. Zakim D, Boyer TD: Hepatology: A Textbook of Liver Disease. 4th ed. Philadelphia: W. B. Saunders, 2002.
36. Davis B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
37. Susla G, Atkinson AJ Jr: Effect of liver disease on pharmacokinetics, in: Atkinson AJ Jr, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP (eds.), Principles of Clinical Pharmacology. San Diego, CA: Academic Press, 2001;63-74.